Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by CMHarring218431on Dec 04, 2023 11:22am
113 Views
Post# 35767103

RE:RE:RE:Roche to acquire Carmot Therapeutics.

RE:RE:RE:Roche to acquire Carmot Therapeutics.

Can't comment on any important relationships the board or management has developed. However, upon re reading the biography's of the Board, it appears that their careers have been immersed in the development of biotechnology and life sciences. Based solely on credentials it would appear these folks should be capable of producing a market strategy that promotes shareholder desires. At the very least, they have been educated in either the business end or medical or both. Their working knowledge in the field of biosciences should enable them to work together synergistically to produce. Many many boards of directors come from all different industries etc. The important question is ....are they involved enough, do they meet/talk enough or are they acting in their own interests and just enjoy another credential attached to the resume. 

<< Previous
Bullboard Posts
Next >>